Print
Daniel Duprez, MD, PhD

Philosophy of Care:

I am dedicated to helping to improve early detection of cardiovascular disease and consequently trying to look for new effective therapeutic approaches to educate these strategies on a national and international level.

Medical Title:

Cardiologist

Academic Appointments:

Professor, Department of Medicine, Cardiovascular Division, University of Minnesota; Donald and Patricia Garofalo Chair for Preventive Cardiology; Director of Research, Rasmussen Center for Cardiovascular Disease Prevention; Associate Director, Cardiovascular Clinical Trials Center

Services:

Heart Care
University of Minnesota Medical Center, Fairview:
Heart Care

Specialties:

Cardiology

Clinical Interests:

  • Cardiovascular disease prevention (primary, secondary)
  • Arterial hypertension
  • Lipid disorders
  • Early Cardiovascular Disease
  • Vascular diseases (arterial, venous, lymph)

Languages Spoken:

Dutch, English, French, German

Education:

Medical School
University of Ghent, Belgium

Site of Residency
University of Ghent, Belgium

Site of Fellowship
Mayo Clinic, Rochester;
University of Ghent, Belgium

Board Certifications:

Cardiology

Hospital Privileges:

University of Minnesota Medical Center, Fairview

Jan-Frans Heymans Prize, period 1986-1987 of the Royal Academy of Medicine of Belgium

Prize Foundation Prof. Dr. G. Verdonck 1997-1999 of the Royal Academy of Medicine of Belgium

Prize of the Foundation Dr Karel-Lodewijk Verleysen, period 1998-2001 of the Royal Academy of Medicine of Belgium

Fellow of the American Heart Association; Fellow of the American College of Cardiology

Fellow of the American Society of Hypertension; Member of the National Lipid Association; Fellow of the European Society of Cardiology

Duprez DA. Is Vascular Stiffness a Target for Therapy? Cardiovasc Drugs and Therapy 2010;24:305-310.

Duprez D. Coronary Artery Calcification, an Improvement in Risk Classification, Need for Re-Appraisal. J Am Coll Cardiol. 2010;56:1415-417.

Duprez DA, Kuller LH, Tracy R, Otvos J, Cooper D, Hoy J, Neuhaus J, Paton NI, Friss-Moller N, Lampe F, Liappis AP, Neaton JD for the INSIGHT SMART Study Group. Lipoprotein Particle Subclasses, Cardiovascular Disease and HIV Infection. Atherosclerosis 2009;524-529.

Cohn JN, Duprez DA. Time to Foster a Rational Approach to Preventing Cardiovascular Morbid Events. J Am Coll Cardiol 2008;52:327-329.

Duprez DA. Systolic Hypertension in the Elderly: Addressing an Unmet Need. Am J Med 2008;121;179-184.

Duprez DA. Does it Matter How You Lower Blood Pressure in Patients with Uncomplicated Hypertension? Weighing the Evidence. Curr Atherosclerosis Rep 2007; 9:352-358.

Duprez DA, Florea N, Jones K, Cohn JN. Beneficial Effects of Valsartan in Asymptomatic Individuals with Vascular or Cardiac Abnormalities. J Am Coll Cardiol 2007;50:835-839.

Duprez DA. Role of the renin-angiotensin-aldosterone system in vascular remodeling an inflammation: a clinical review. J Hypertens. 2006;24:983-91.

Duprez DA, Somasundaram PE, Sigurdsson G, Hoke L, Florea N, Cohn JN. Relationship between C-reactive protein and arterial stiffness in an asymptomatic population. J Hum Hypertens 2005;19:515-519.

Duprez DA, Kaiser D, Whitwam W, Finkelstein S, Belalcazar A, Patterson R, Glasser S, Cohn J. Determinants of radial artery pulse wave analysis in asymptomatic individuals. Am J Hypertension 2004;17:647-653.

Cohn JN, Hoke L, Whitwam W, Sommers PA, Taylor AL, Duprez D, Roessler R, Florea N. Screening for early detection of cardiovascular disease in asymptomatic individuals. Am Heart J 2003; 146:679-685.

 
 
Site Help and Feedback Site Help and Feedback
Visit Other Fairview Sites
 
 
(c) 2012 Fairview Health Services. All rights reserved.